6 completed, 4 active not recruiting, 1 suspended. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 2, Suspended 1 |
| Phase 2 | 6 | Completed 3, Active not recruiting 2, Suspended 1 |
Follow CD20 Positive: new trials by email Literature Review of CD20 Positive trials Research Report on CD20 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Acalabrutinib, Venetoclax - Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2019-08-13 | 2026-08-10 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 48 | 2016-04-11 | 2024-09-24 |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Carboplatin, Etoposide, Ibrutinib - CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2014-09-12 | 2018-01-26 |
| Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Carboplatin, Carfilzomib, Etoposide - CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 29 | 2014-04-17 | 2026-08-26 |
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Rituximab - CCND1 Positive, CCND2 Positive | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 113 | 2013-07-15 | 2026-07-08 |
| Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma Ipilimumab, Laboratory Biomarker Analysis, Rituximab - CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 32 | 2012-11-19 | 2018-04-11 |
| Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 2 | Completed | M.D. Anderson Cancer Center | 72 | 2011-07-12 | 2021-05-03 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine - CD20 Positive, Chronic Lymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 60 | 2009-02-17 | 2019-06-03 |
| Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bortezomib - CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2007-02-13 | 2019-09-10 |
Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, Follicular (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, T-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma (10) · Lymphoma, Non-Hodgkin (10) · Lymphoma, B-Cell (5) · Hematologic Diseases (4) · Leukemia (3) · Leukemia, Lymphoid (3) · Chronic Disease (2) · Disease Attributes (2)
CT-P10 (8) · Rituximab (8) · Cyclophosphamide (3) · Etoposide (3) · Methotrexate (3) · ibrutinib (3) · merphos (3) · Antilymphocyte Serum (2) · Carboplatin (2) · Cytarabine (2) · Doxorubicin (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Ifosfamide (2) · Tacrolimus (2)
M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (2) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1) · Roswell Park Cancer Institute (1)
United States (11)
Craig Sauter (1) · Elias Jabbour (1) · Francisco Hernandez-ILizaliturri (1) · Issa Khouri (1) · Issa Khouri, MD (1) · Joseph Tuscano (1) · Loretta J Nastoupil (1) · Michael L Wang, MD (1) · Reem Karmali, MD (1) · Sarah Larson, MD (1)
PMID 25145344, PMID 26640039, PMID 29386196, PMID 32589978, PMID 34138471, PMID 34797699, PMID 35622074, PMID 37632592, PMID 37985359, PMID 40706069
P30CA016672 (2), P30CA008748 (1), P30CA033572 (1), P30CA060553 (1), R01CA136907 (1), U01CA062505 (1), UM1CA186704 (1), UM1CA186717 (1)